QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation“) (TSXv: GSD), a clinical stage biopharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, today announces that Professor George G. Zhanel has joined the Corporation’s Scientific Advisory Board for its Cannabinoids-based pharmaceutical program.
Dr. Zhanel received his Ph.D. in the Department of Medical Microbiology/Infectious Diseases at the Faculty of Medicine, University of Manitoba and a Doctor of Clinical Pharmacy at the University of Minnesota. He is presently Professor in the Department of Medical Microbiology/Infectious Diseases, College of Medicine; Course Leader, Infectious Diseases Teaching, College of Medicine, University of Manitoba; Coordinator of Antibiotic Resistance in the Departments of Medicine and Clinical Microbiology, Health Sciences Centre; and Research Director of the Canadian Antimicrobial Resistance Alliance (CARA). Dr Zhanel is the founding and Chief Editor of the Canadian Antimicrobial Resistance Alliance (CARA) website (www.can-r.ca).
Dr. Zhanel has published over 1000 papers, chapters and abstracts in the area of antimicrobial resistant infections. He has presented over 1000 lectures as an invited speaker at international, national, and local meetings speaking on the topics of antimicrobial resistant infections as well as treatment and prevention of infectious diseases in Canada, United States, Central and South America, Western and Eastern Europe including Russia, Australia, Southern and Northern Africa, the Middle East and Asia.
Professor Zhanel commented, “I am really excited to join the scientific board to bring value to the cannabinoids-based pharmaceutical program”.
"Professor Zhanel is known globally both for his extensive research in the field of Infectiology. We are delighted that he has agreed to join our Scientific Advisory Board. With his unique experience in the field of Infectious Diseases, we are confident the Professor Zhanel will be able to make a significant contribution to our cannabinoids-based pharmaceutical program ", said Dr Andre P. Boulet, President and Chief Executive Officer of Devonian.
Devonian Health Group Inc. is a late stage biopharmaceutical corporation with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription botanical drugs from plant materials and algae for the treatment of inflammatory-autoimmune diseases including but not limited to ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian’s focus is further supported by a US-FDA set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian Health Group Inc. was incorporated in 2013 and is headquartered in Québec, Canada where it owns a state-of-the art extraction facility with full traceability ‘from the seed to the pill’. Acquired in 2018, Altius Healthcare Inc., its commercial division, brings opportunities for further diversification and growth potential. Devonian is traded publicly on the TSX Exchange (TSXv:GSD).
For more information, visit www.groupedevonian.com.
Forward Looking Statements
This press release contains forward-looking statements about Devonian’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Devonian’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical and cosmeceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Devonian to take advantage of business opportunities in the pharmaceutical and cosmeceutical industries, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Devonian’s prospectus dated April 21, 2017 under the heading “Risk Factors” related to Devonian’s business. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.